Intensity Therapeutics INTS
NASDAQ INTS
$3.38 -0.05 (-1.31%)
As of: Sep 30, 2026 · 2:44 PM EDT

Intensity Therapeutics (INTS) Depreciation and Depletion (2022 - 2023)

Updated

Intensity Therapeutics' Depreciation and Depletion was $2,019 in Q3 2023, down 95.5% from $44,977 a year earlier.

Analysis

Intensity Therapeutics (INTS) Depreciation and Depletion (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Depletion (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn -
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 194.00 Mn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn -
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 98.00 Mn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Intensity Therapeutics 10.01 Mn 10.01 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 2,019.00
Sep 30, 2022 44,977.00
API Access

Intensity Therapeutics Depreciation and Depletion API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-depletion&ticker=INTS&period=max&api_key=YOUR_API_KEY